GPT Healthcare Q1 FY27: ARPOB Gains and a Clear Path to Scale

GPT Healthcare Limited began FY27 with a quarter that looked stronger on earnings than on occupancy. Revenue from operations rose to Rs 126.2 crore in Q1 FY27, up 17.8 percent year on year. EBITDA grew faster at Rs 26.2 crore, up 38.5 percent, as the EBITDA margin improved to 20.4 percent from 17.4 percent a year ago. Profit after tax came in at Rs 12.7 crore, up 65.7 percent, with a PAT margin of 9.9 percent.

The operating story had two distinct layers. First, the network saw pricing and case-mix improvement, with average revenue per occupied bed (ARPOB) rising to Rs 42,350. Second, occupancy remained muted at 45.5 percent, largely because the newest hospital in Raipur is still ramping up. Excluding Raipur, mature hospitals ran at 58.07 percent occupancy in the quarter, which is closer to the platform’s historical range.

In short, the quarter showed that GPT Healthcare can lift realizations even when network occupancy is held back by a new unit. For investors, the key question is whether management can convert this ARPOB-led momentum into sustained operating leverage as occupancy moves toward its stated target of around 70 percent.

Q1 FY27 in numbers: Growth led by realizations

The company’s proximity-based model in Eastern India is built around neighborhood tertiary-care hospitals. GPT Healthcare operates five hospitals: Salt Lake, Agartala, Dum Dum, Howrah, and Raipur. The network has 719 beds and a large clinician base, with 115 full-time consultants and 630 visiting consultants. The platform also highlights advanced clinical capabilities, including more than 800 cumulative robot-enabled surgeries.

Financially, Q1 FY27 reflected a mix of stable mature hospitals and a small but rising contribution from Raipur. Of the Rs 126.2 crore in Q1 revenue, mature hospitals contributed Rs 115.6 crore while Raipur contributed Rs 10.6 crore. The company also reported other operating income of Rs 2.0 crore, taking total revenue to Rs 128.2 crore.

Cost lines rose as expected with growth, but EBITDA expanded sharply. Material costs were Rs 24.1 crore and employee costs were Rs 23.2 crore in Q1 FY27, while other expenses were Rs 54.6 crore. Depreciation was Rs 6.9 crore and finance cost was Rs 2.2 crore, leading to profit before tax of Rs 17.2 crore.

A notable improvement was the sharper year-on-year growth in EBIT and profit. EBIT increased 51.6 percent year on year to Rs 19.3 crore, and profit after tax rose 65.7 percent year on year. Sequentially, PAT was lower than Q4 FY26, but the quarter-on-quarter comparison is less meaningful given seasonality and the ongoing ramp-up of Raipur.

The operational metrics explain the earnings shape. Average length of stay fell to 3.35 days in Q1 FY27 from 3.48 days in Q1 FY26. Lower length of stay can support higher throughput over time, but only if demand and doctor availability convert that throughput into admissions. In the near term, the stronger signal was ARPOB, which increased meaningfully despite occupancy softness.

Hospital network: Mature base holds, Raipur ramps

GPT Healthcare’s hospital-wise disclosure shows where the network is strong and where execution is still underway.

Dum Dum remains the highest-occupied hospital, posting 65.4 percent occupancy in Q1 FY27, along with ARPOB of Rs 43,041. The hospital is supported by its renal transplant program, with more than 700 transplants completed. Management also notes an expansion path within the specialty base, including respiratory ICU and cardiac surgery services to be launched shortly.

Salt Lake delivered 62.4 percent occupancy and the highest ARPOB in the network at Rs 45,282. The hospital has strengthened its leadership in robotic-assisted surgery, with more than 800 cumulative procedures highlighted at the network level and a large base executed from Salt Lake. Its clinical focus on robotic gastro and bariatric surgeries is consistent with higher realizations, and the hospital also offers specialized diabetic foot care and advanced gastroenterology.

Agartala’s quarter was mixed. Occupancy was 45.3 percent, but ARPOB rose sharply to Rs 41,573. The hospital has expanded its oncology platform with PET scan and Linear Accelerator facilities, and has completed over 700 radiation therapy procedures. The increase in ARPOB suggests the oncology build-out is already changing the clinical mix, even if volumes have not yet fully scaled.

Howrah continues to be an operating leverage story in progress. Occupancy improved to 45.2 percent and ARPOB rose to Rs 39,435. The hospital has launched MAKO robotic knee replacement surgeries and expanded emergency capacity from 2 to 10 beds. It also achieved EBITDA breakeven within 8 months of inauguration, a metric the company positions as evidence of execution discipline.

Raipur is the primary swing factor for consolidated occupancy and for near-term margins. In Q1 FY27, occupancy was 17.4 percent with ARPOB of Rs 42,320 and revenue of Rs 10.6 crore. The hospital commenced operations in May 2025 and is positioned as a quaternary care unit for a broad catchment including Raipur, Bilaspur, Durg, and Bhilai. Management notes that the renal transplant program has commenced, chemotherapy and oncology surgeries are fully operational, and the hospital has received a license for liver transplant services. The unit is also equipped with high-end infrastructure including a 3 Tesla MRI and a cardiac catheterization lab.

This distribution highlights a key feature of GPT Healthcare’s model. Even at relatively modest occupancy in some hospitals, ARPOB levels remain high across the network. That supports margin resilience when the case mix improves, but it does not fully offset the drag from underutilized capacity, especially in a new unit like Raipur.

What changed this quarter: Case mix, technology, and execution

Management attributes the increase in ARPOB to improved clinical mix and operating efficiencies. That theme shows up in the operational highlights across hospitals.

Robotic-assisted surgery continues to be a central lever. Salt Lake has built a leadership position in robotic-assisted procedures, while Howrah has begun MAKO robotic knee replacement surgeries. In hospitals, robotics tends to matter in two ways: it can support higher realization procedures, and it can strengthen brand perception among referring doctors and patients. In GPT Healthcare’s case, robotics appears linked to ARPOB growth, with Salt Lake setting the pace.

Oncology is another visible lever, particularly at Agartala and Raipur. Agartala’s end-to-end oncology offering now includes PET scan and Linear Accelerator facilities, and the hospital has completed more than 700 radiation therapy procedures. Raipur is ramping high-acuity specialties including oncology and transplant services. The direction is consistent with the stated strategy of increasing the share of complex and high-acuity procedures to lift ARPOB.

Transplants remain a differentiator within the network. Dum Dum’s established renal transplant program supports its high occupancy, and Raipur has commenced renal transplants and received a license for liver transplant services. Transplant programs are difficult to replicate quickly, and they can improve payer mix and brand credibility. But they also demand strong clinical teams and high compliance standards, which means scaling must be carefully managed.

The company also highlights its technology-enabled initiatives beyond the operating room. SPARSH, a healthcare-at-home service for senior citizens, offers medical support for an annual fee of INR 500 and includes monthly doctor visits and discounts across OPD, IPD, diagnostics, and physiotherapy. The ILS-My Health app enables appointment booking and access to medical records, while HMIS supports electronic medical records and a broader digital framework. These initiatives are not large revenue drivers in the presentation, but they signal a focus on patient retention and operating efficiency.

Strategy and investor lens: Scaling to 1,000 beds with ROCE discipline

GPT Healthcare’s medium-term plan is explicit. Management aims to maintain network occupancy at around 70 percent, improve ARPOB through a higher share of complex procedures, expand capacity to more than 1,000 beds over the next two years, and sustain long-term ROCE of approximately 25 percent.

The near-term performance shows why this balance matters. FY26 revenue from operations was Rs 478.5 crore and EBITDA was Rs 90.1 crore, with EBITDA margin at 18.84 percent. But FY26 PAT declined 15.43 percent to Rs 42.2 crore and ROCE moderated to 16.5 percent. The company remains net-debt free, with net debt to equity at -0.12 in FY26, which gives flexibility. Still, returns have room to recover toward the stated long-term target, and that recovery is likely tied to ramp-up execution.

Raipur’s breakeven timeline is therefore important. Management states the hospital remains on track to achieve operational breakeven by Q3 FY27. If the unit moves from 17.4 percent occupancy toward more normalized levels, fixed-cost absorption should lift margins. Investors will likely watch two indicators: occupancy growth in Raipur and whether ARPOB stays firm as volumes scale.

Expansion is also moving beyond the current network. The company has signed an MoU for a 155-bed hospital in Jamshedpur, with INR 75 crore investment, targeted to commence by end-FY27. It also plans entry into Tier II cities including Uttar Pradesh, Assam, and Odisha, and select Tier I locations in Eastern India. The presentation notes that land and building will be funded by developers, while operations will run on fixed rental arrangements. This is positioned as a capital-efficient model to enable faster ROCE accretion.

The broader industry context in the presentation is favorable, including policy-backed healthcare spending, a bed shortfall in India, and medical tourism potential in Eastern India with patients from Bangladesh, Nepal, and Bhutan. But GPT Healthcare’s results suggest the company’s immediate opportunity is more internal: converting its clinical investments into higher occupancy while protecting ARPOB.

Closing view: A quarter that proved the earnings engine

Q1 FY27 showed a company that can grow profits faster than revenue when case mix improves. Revenue rose 17.8 percent year on year, while EBITDA rose 38.5 percent and PAT rose 65.7 percent. ARPOB climbed to Rs 42,350, indicating that the network is pushing deeper into complex procedures across robotics, oncology, cardiology, and transplants.

The softer point remains utilization. At 45.5 percent occupancy, the network is below the company’s stated direction of around 70 percent, though mature hospitals at 58.07 percent show the underlying base is steadier than the consolidated number suggests. The ramp-up at Raipur is the largest variable in the near term, and management’s Q3 FY27 breakeven target sets a clear timeline for investors.

The quarter’s theme is disciplined execution with a visible operating lever. If GPT Healthcare can lift occupancy while holding ARPOB at current levels, the financial model has room to expand margins and recover returns. And with a stated plan to scale to 1,000 beds using capital-efficient structures, the next phase will test whether the platform can replicate its mature-hospital playbook while keeping ROCE in focus.